Login to Your Account

‘SMART’ Money Backs Catabasis $32.4M Series B

By Marie Powers
Staff Writer

Thursday, November 14, 2013

Lightstone Ventures led a $32.4 million Series B round for Catabasis Pharmaceuticals Inc., designed to complete a Phase II study of lead compound CAT-2003, currently under way in hypertriglyceridemia and in combination with statins in hypercholesterolemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription